Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-12-31
1999-05-11
Naff, David M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 54, 514 56, 514 59, 514 57, 424538, 536 20, 536 21, A61K31/73;31/725;35/56
Patent
active
059027983
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL AREA
The present invention relates to new agents to accelerate, stimulate or promote the healing of dermal wounds. The invention also includes a process for the treatment of dermal wounds.
BACKGROUND OF THE INVENTION
With regard to wound ointments and similar agents for the treatment of dermal wounds, i.e. disorders in the form of wounds in the epidermis arising through accident, surgical incision or without exterior influence, for example wounds in connection with acne, so called chaps or the like, the market is flooded by products of different kinds. These products are characterized by containing as active constituents active substances of different kinds, for example antibiotics, antiinflammatory etc. whose action primarily is not directed to stimulate healing but instead are directed to act as desinfectants or in some other manner perform a cleaning action. The components contained are therefore often of such a character that they are not biodegradable to a desired degree, the storage stability also leaving something to be desired. Therefore, for the purpose of improving storage stability known products for dermal treatment often contain one or several excipients to prevent or delay decomposition, and among such excipients there may be mentioned sodium disulphate, dithiotreitol and others.
SUMMARY OF THE INVENTION
The present invention has for an object to provide agents which accelerate, stimulate or promote healing of dermal wounds.
Another object of the invention is to provide such an agent, at whose use no inflammatory response will arise.
Yet another object of the invention is to provide agents which are bioacceptable and biodegradable without giving raise to deleterious decomposition products.
A further object of the invention is to provide a process for the treatment of dermal wounds.
For these and other objects which will be clear from the following disclosures there is provided by the present invention a new use of chitosan in combination with a first polysaccharide selected from heparin, heparan sulfate and dextran sulfate for the manufacture of an agent that accelerates, stimulates and/or promotes healing of dermal wounds.
In the present context the expression "dermal wound" is intended to cover any disorder in association with dermis in the form of regular wounds arising through accident, surgical incision or in another manner by exterior influence, or wounds which have arisen without exterior influence, such as acne, so called chaps or other fissures in the dermis.
The first polysaccharide used can be present in the agent in admixture with a chitosan and possible other ingredients, but can also be immobilized to the chitosan in three different ways. Immobilization can thus take place by ionic bond, by covalent bond or by mechanical inclusion in the chitosan in connection with its precipitation from a solution. A process for the covalent binding of the relevant polysaccharide to a substrate carrying amino groups, which substrate can be constituted by chitosan is described in U.S. Pat. No. 4,613,665.
As a polysaccharide it is particularly preferred to use heparin or heparan sulfate, both of which are commercially available on the market from several manufacturers. Also partially hydrolyzed forms of the polysaccharide can, of course, also be used provided that the biological activity is maintained.
The agent for healing of dermal wounds involved in the present invention can be presented in different physical forms, for example as powders, ointments, pastes, gels, suspensions or solutions. The form used is, of course, adapted to the dermal disorder to be treated. For certain types of wound treatment the treatment agent according to the invention may also be presented in the form of thin films or membranes.
One of the main components in the subject treatment agent for dermal wounds is thus chitosan which is a linear 1,4-bound polysaccharide built up from .beta.-D-glucose amine entities. The chitosan is manufactured by N-deacetylation of chitin, a polymer forming the shell of in
REFERENCES:
patent: 4326532 (1982-04-01), Hammar
patent: 4378017 (1983-03-01), Kosugi et al.
patent: 4532134 (1985-07-01), Malette et al.
patent: 4572906 (1986-02-01), Sparkes et al.
patent: 4879282 (1989-11-01), Saliba, Jr.
patent: 5002582 (1991-03-01), Guire et al.
patent: 5037810 (1991-08-01), Saliba, Jr.
patent: 5116824 (1992-05-01), Miyata et al.
Saliba, Jr., et al., JAMA, 225:261-269, 1973.
Journal of Periodontology, vol. 62, No. 10, 1991, S. Pitaru et al., "Heparan Sulfate and Fibronectin Improve the Capacity of Collagen Barriers to Prevent Apical Migration of the Junctional Epithelium", p. 598.
Biomaterials, vol. 14, No. 12, 1993, R.A.A. Muzzarelli et al., "Osteoconductive properties of methylpyrrolidinone chitosan in an animal model", p. 925.
Department of Histology, vol. 64, 1989, L. Peter Nilsson, "Effects of Hyperbaric Oxygen Treatment on Bone Healing", pp. 19-20.
Gouda Ibrahim
Larm Olle
Kerr Janet M.
Medicarb AB
Naff David M.
LandOfFree
Method of promoting dermal wound healing with chitosan and hepar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of promoting dermal wound healing with chitosan and hepar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of promoting dermal wound healing with chitosan and hepar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-245715